Sanofi Enters the mRNA Patent War: Lawsuits, Patents, and the Billion-Dollar Fight Over Vaccine Technology

• Translate Bio Inc. v. Moderna Inc. — No. 2:26-cv-08690
• Translate Bio Inc. v. Pfizer Inc. — No. 2:26-cv-08697

Critically, Sanofi has signaled a strategy focused on financial compensation rather than market disruption. A company spokesperson stated that Sanofi is "seeking fair compensation for use of its patented technology" and is not seeking to block sales of any vaccines . This approach—pursuing damages without injunctions—is consistent with the strategy used by other plaintiffs in these high-stakes disputes .

The Patents and Products at the Center of the Dispute

Patents Asserted by Translate Bio

Sanofi alleges that the vaccines from Moderna and Pfizer/BioNTech infringe up to 10 patents held by Translate Bio . These patents do not cover the mRNA sequence itself but rather the critical enabling technologies that get the mRNA into the body’s cells safely and effectively. The disputes are centered on two key areas:

1. Lipid Nanoparticle (LNP) Compositions and Methods: The patents cover the compositions and methods for manufacturing LNPs, the fatty delivery vehicles that encapsulate fragile mRNA molecules and transport them into human cells. Translate Bio holds multiple patents on specific LNP manufacturing processes, including low-citrate-concentration encapsulation, ambient-temperature formulation, and pre-formed LNP mixing techniques . This is the most heavily contested area of the entire mRNA IP landscape .

2. mRNA Purification Technologies: Additional patents in the suit cover methods for purifying mRNA, a crucial step in manufacturing that removes contaminants and ensures the vaccine's safety and efficacy .

Products Accused of Infringement

• Moderna: The lawsuit claims that three of Moderna’s products infringe the Translate Bio patents: Spikevax (its original COVID-19 vaccine), mNexspike (an updated COVID-19 vaccine), and mResvia (its RSV vaccine) .
• Pfizer: The suit alleges that Pfizer’s COVID-19 vaccine Comirnaty (co-developed with BioNTech) infringe eight of the ten patents .

What Sanofi is Seeking: Royalties and Damages

No specific royalty percentage or financial figure has been publicly disclosed in the initial legal complaints . Sanofi’s stated position is that it seeks "fair compensation" . However, the potential financial stakes are enormous. The vaccines named in the lawsuits have generated tens of billions of dollars in cumulative sales revenue. The industry publication Life Sciences IP Review notes that Sanofi is seeking damages from vaccines "worth billions" .

The lawsuits are seeking monetary damages in the form of reasonable royalties rather than an injunction to stop sales, a common pattern in these disputes .

The Broader mRNA Patent War: A Landscape of Litigation

Sanofi's lawsuits are not an isolated event but the latest escalation in a dense and multi-jurisdictional war over foundational mRNA and LNP intellectual property. Every major player—Moderna, Pfizer/BioNTech, Sanofi/Translate Bio, CureVac, Arbutus, and Genevant—is either suing or being sued, often both .

Here is a timeline of the key disputes shaping the landscape:

2022–Ongoing: Moderna vs. Pfizer/BioNTech

This is the foundational dispute of the mRNA patent wars. In August 2022, Moderna sued Pfizer and BioNTech, alleging that they copied Moderna’s patented technology, specifically the 1-methylpseudouridine (m1Ψ) mRNA modification and broader mRNA/LNP technology . The case is ongoing, with complex twists including the partial pausing of the U.S. case in 2024 to allow the USPTO to review patent validity and a UK Supreme Court appeal docketed in 2025 . Moderna has also filed additional lawsuits against Pfizer and BioNTech .

2023–Ongoing: Genevant & Arbutus vs. Pfizer/BioNTech

Genevant and Arbutus, two biotechnology firms that hold foundational patents on LNP technology, filed a lawsuit against Pfizer and BioNTech in 2023, alleging that their vaccine infringes their LNP patents . This case is still in progress .

March 2026: Moderna’s $2.25 Billion Settlement with Arbutus/Genevant

In a landmark development that cleared a major legal overhang for Moderna, the company agreed to pay Arbutus and Genevant up to $2.25 billion to settle their LNP patent disputes. The payout includes a $950 million upfront payment (due July 2026) and an additional $1.3 billion contingent on the outcome of a separate appeal . Notably, as part of this settlement, Moderna owes no future royalties on its pipeline of future vaccines . This massive payout underscores just how valuable and contested LNP technology is.

2025–2026: A Flurry of Counter-Claims and New Actions

The legal landscape has become increasingly crowded and aggressive. In February 2026, BioNTech countersued Moderna, claiming that Moderna's next-generation COVID-19 vaccine infringes one of its patents . In April 2026, CureVac initiated a lawsuit against Moderna for patent infringement . There have also been significant wins and losses for both sides in Europe, with the European Patent Office (EPO) upholding a key Moderna patent in July 2025 , and a German court ruling in favor of BioNTech earlier that same year .

Key Takeaway

Sanofi’s entry into the fray marks a significant expansion of the mRNA patent conflict. The disputes are now centered on three core technology pillars:

1. mRNA Sequence Modifications: Primarily the 1-methylpseudouridine modification, a key innovation that reduces the innate immune response to the synthetic mRNA, allowing for safer and more effective vaccines . The core patents for this are owned by the University of Pennsylvania and exclusively licensed to Moderna.
2. Lipid Nanoparticle (LNP) Delivery Systems: The most heavily contested area, involving patents from Arbutus, Genevant, Acuitas, and now Translate Bio (Sanofi). These patents cover the composition and manufacturing of the LNP "packaging" .
3. mRNA Manufacturing/Purification Methods: Patents covering the process of producing and purifying the mRNA itself, which is the target of Sanofi’s second set of claims .

Sanofi's move specifically targets the LNP delivery and purification layer, which remains one of the highest-stakes and most crowded areas of the entire patent landscape. The outcome of these cases will not only determine who pays whom for the COVID-19 vaccines but will also shape the financial and competitive dynamics for the next generation of mRNA-based therapeutics for years to come.